F-1/A: Zhong Yuan Bio-Technology Holdings Files Amendment for Public and Resale Offerings

Zhong Yuan Bio-Technology Holdings Limited files an amendment to its registration statement for a proposed public offering of 1,100,000 ordinary shares and a resale offering of up to 1,000,000 ordinary shares by a selling shareholder.

Summary

• Zhong Yuan Bio-Technology Holdings Limited has filed Amendment No. 10 to its Form F-1/A registration statement with the SEC.
• The filing pertains to a proposed public offering of up to 1,100,000 ordinary shares by the company.
• It also includes a resale prospectus for the potential resale of up to 1,000,000 ordinary shares by Mr. Yu Chang, a shareholder.
• The company will not receive any proceeds from the sale of shares by Mr. Chang.
• The company intends to list its Ordinary Shares on the Nasdaq Capital Market.
• The company anticipates the public offering price of the Ordinary Shares will be between US$5.00 and US$7.00 per Ordinary Share.
• The company is required to file with the CSRC before its offering and listing are completed.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
• The company's independent registered public accounting firm is Centurion ZD CPA & Co., headquartered in Hong Kong.
• The company's operations are conducted in China through its operating subsidiaries.
• The company's equity structure is a direct holding structure.
• The company has not paid dividends or made distributions to U.S. investors.
• The company may transfer cash proceeds raised from overseas financing activities to its subsidiaries via capital contribution or shareholder loans.
• The company's PRC subsidiaries' ability to distribute dividends is based upon their distributable earnings.
• The company may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from its profits, if any.
• The company has granted the underwriters an option to purchase up to an additional 165,000 Ordinary Shares at the offering price, less underwriting discounts and commissions, within 45 days from the date of this prospectus to cover over-allotments, if any.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the details of the proposed public and resale offerings. While it mentions risks, it also highlights the company's plans and intentions, resulting in a neutral to slightly positive sentiment.

Positives

• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
• The company's equity structure is a direct holding structure, which facilitates cross-border transfer of funds within the corporate group.
• The company has been granted an option to purchase up to an additional 165,000 Ordinary Shares at the offering price, less underwriting discounts and commissions, within 45 days from the date of this prospectus to cover over-allotments, if any.

Negatives

• The company will not receive any proceeds from the resale offering by Mr. Yu Chang.
• The company is required to file with the CSRC before its offering and listing are completed.
• The company has not paid dividends or made distributions to U.S. investors.
• The company may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from its profits, if any.

Risks

• The Chinese government may exercise significant oversight and discretion over the conduct of the company's business and may intervene in or influence its operations at any time.
• Future action by the Chinese government could significantly limit or completely hinder the company's ability to offer or continue to offer securities to investors.
• The company's Ordinary Shares may be prohibited from trading on a U.S. exchange if its auditor cannot be fully inspected by the PCAOB.
• The company may be subject to administrative penalties if it fails to complete the required filing procedures with the CSRC.
• The company's PRC subsidiaries' ability to distribute dividends is based upon their distributable earnings and is subject to PRC regulations.

Future Outlook

The company intends to list its Ordinary Shares on the Nasdaq Capital Market and use the net proceeds from the offering for research and development of new drugs for neurological diseases and for working capital and other general corporate purposes.

Industry Context

The document does not provide specific details about the broader industry trends or competitors beyond the company itself.

Stakeholder Impact

• Potential dilution for existing shareholders due to the issuance of new shares.
• New investors will be subject to the risks outlined in the prospectus.
• The company's ability to execute its business plan will be dependent on the success of the offering.

Next Steps

• The company needs to obtain approval from the Nasdaq Stock Market to list its Ordinary Shares.
• The company is required to file with the CSRC before its offering and listing are completed.
• The underwriters expect to deliver the Ordinary Shares to the purchasers against payment on or about [], 2024.

Key Dates

Keywords

public offering, resale offering, ordinary shares, CSRC, PCAOB, China, Zhong Yuan Bio-Technology, HFCAA, securities, listing